Eva Aspalter
The power of collaboration!
In up to 90 percent of patients suffering from the metabolic disease, the situation improved significantly. In the USA, the drug Trikafta, following an accelerated procedure, is already approved for patients aged twelve years and older. An application for approval has been submitted to the European authority EMA. Spiegel Online will report on 4 November 2019.
The international team of ATMOS Resort & Research has been working hard for years to attract attention, find new solutions and generate donations. This hard work is slowly bearing fruit.
Donations benefit research
The ATMOS donation philosophy provides that every Euro donated is passed on without deductions in equal parts to our two partner organisations, the Cystic Fibrosis Aid Upper Austria as emergency aid and the CF Centre of the Children’s Hospital Vienna for research purposes. The head of this CF center, Dr. Sabine Renner, also supervised participants of the above mentioned study and reports:
“Already after two weeks, patients are fitter and have improved their respiratory function and show the enormous improvement in lung function.”
This proves that our donations go where they are really needed.
A world without mucoviscidosis
Success stories such as these motivate us to pursue even more vehemently our major goal of eradicating the disease cystic fibrosis (cystic fibrosis) within the next ten years.
A constantly growing community and number of supporters prove that our path is the right one. For a world without cystic fibrosis.
from left to right: Dr. Sabine Renner (CF-Zentrum Kinderklinik wien), OA Franz Eitelberger (CF-Ambulanz Klinikum Wels), Chris Müller (ATMOS), Ingo Huber (Delta) mit Kollegen, Elisabeth Jodlbauer-Riegler (Mukoviszidose Hilfe OÖ) with daughter Anna Jodlbauer (CF patient)